Your browser doesn't support javascript.
loading
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).
Marabelle, A; Andtbacka, R; Harrington, K; Melero, I; Leidner, R; de Baere, T; Robert, C; Ascierto, P A; Baurain, J-F; Imperiale, M; Rahimian, S; Tersago, D; Klumper, E; Hendriks, M; Kumar, R; Stern, M; Öhrling, K; Massacesi, C; Tchakov, I; Tse, A; Douillard, J-Y; Tabernero, J; Haanen, J; Brody, J.
Affiliation
  • Marabelle A; Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: aurelien.marabelle@gustaveroussy.fr.
  • Andtbacka R; Surgical Oncology Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA.
  • Harrington K; The Royal Marsden/The Institute of Cancer Research, National Institute for Health Research Biomedical Centre, London, UK.
  • Melero I; Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain.
  • Leidner R; Providence Cancer Center, Earle A. Chiles Research Institute, Portland, USA.
  • de Baere T; Department of Image Guided Therapy, Gustave Roussy, Université Paris-Saclay, Villejuif.
  • Robert C; Department of Dermatology, Institute Gustave-Roussy, Paris, France.
  • Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
  • Baurain JF; King Albert II Cancer Institute, Cliniques Universitaires St Luc, Université Catholique de Louvain, Brussels, Belgium.
  • Imperiale M; Nektar Therapeutics, San Francisco.
  • Rahimian S; Idera Pharmaceuticals, Exton, USA.
  • Tersago D; Clinical Development, Bioncotech Therapeutics, Madrid, Spain.
  • Klumper E; Lytix Biopharma AS, Oslo, Norway.
  • Hendriks M; Aduro Biotech, Eindhoven, The Netherlands.
  • Kumar R; MedImmune, LLC, Gaithersburg, USA.
  • Stern M; Roche, Zurich.
  • Öhrling K; Amgen Europe GmbH, Zug, Switzerland.
  • Massacesi C; Global Product Development Oncology, Pfizer, USA.
  • Tchakov I; Eisai Ltd, Hatfield, UK.
  • Tse A; Oncology Early Development, Merck & Co., Inc, Kenilworth, USA.
  • Douillard JY; ESMO, Viganello-Lugano, Switzerland.
  • Tabernero J; Medical Oncology Department, Vall d' Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Haanen J; Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Brody J; Division of Hematology and Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai Hospital, New York, USA.
Ann Oncol ; 29(11): 2163-2174, 2018 11 01.
Article in En | MEDLINE | ID: mdl-30295695
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Research Design / Practice Patterns, Physicians' / Clinical Trials as Topic / Practice Guidelines as Topic / Immunotherapy / Neoplasms Type of study: Guideline / Prognostic_studies Aspects: Ethics Limits: Humans Country/Region as subject: Europa Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2018 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Research Design / Practice Patterns, Physicians' / Clinical Trials as Topic / Practice Guidelines as Topic / Immunotherapy / Neoplasms Type of study: Guideline / Prognostic_studies Aspects: Ethics Limits: Humans Country/Region as subject: Europa Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2018 Document type: Article